Moderna's stock is facing significant pressure following a downgrade from Citi, leading to a sharp decline in its market value.
Moderna Inc. (NASDAQ:MRNA) saw its shares tumble by 5.10% today, closing at CA$193.08, as analysts reacted to a downgrade from Citi. This downgrade has raised concerns about the company's valuation amidst its recent stock performance.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$81.23B
52W high
$208.90
52W low
$22.28
1W change
+11.45%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Sep 17, 2026
Wall Street analysts forecast MRNA stock price to fall 41.2% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$119.56
-41.2% Upside
Current Price
C$203.46
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
315.7%
Annualized
90-Day Vol
213.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$243.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$215.94 | C$72.66 – C$641.76 |
| 60 trading days | C$229.18 | C$49.11 – C$1069.46 |
| 90 trading days | C$243.24 | C$36.87 – C$1604.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Moderna's stock faces downward pressure due to analyst concerns over its valuation, despite recent successes in clinical trials.
5.10% decline in Moderna's stock today
Moderna's stock has dropped significantly following a downgrade, highlighting investor concerns about the sustainability of its recent gains.
Bull case
If Moderna continues to succeed in its clinical trials and effectively leverages its innovations, it could regain investor confidence and improve its valuation.
Bear case
The downgrade from Citi suggests that the stock may be overvalued, especially after a significant rally. If the company doesn't meet growth expectations, further declines could follow.
Advertisement
Citi's Downgrade Sparks Decline
Citi downgraded Moderna from Neutral to Sell, raising its price target to $80 from $60. The firm expressed concerns that the stock's valuation had become unjustifiable, particularly after a remarkable 222% increase since the results of the INTerpath-001 trial. This significant downgrade has led to a sharp sell-off, as investors reassess the stock's future prospects.
Market Reaction and Future Outlook
The market's reaction to the downgrade has been swift, with Moderna's stock plummeting in premarket trading and continuing its decline throughout the day. Investors are now questioning whether the recent success in clinical trials will be enough to sustain the stock's high valuation. The pressure on the stock reflects broader concerns in the biotech sector regarding valuation and growth potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
